Dr. Chagpar on Sequencing Therapies for HER2-Positive Breast Cancer

Anees B. Chagpar, MD
Published: Monday, Aug 03, 2015



Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.

Treatment options for patients with HER2-positive breast cancer has significantly expanded in recent years, Chagpar explains. Though she was told that HER2-positive disease would reach high curative rates, similar to childhood leukemia, Chagpar says she was not convinced. However, she became more optimistic after seeing that combinations of targeted therapies demonstrated significant pathological complete response rates in a number of clinical trials.

Over the next decade, Chagpar predicts that HER2-positive disease will become a chronic disease that can be managed with a selection of targeted therapies.
 


Anees B. Chagpar, MD, MA, MPH, MBA, FRCS(C), FACS, associate professor of surgery (oncology), director, The Breast Center at Smilow Cancer Hospital at Yale-New Haven, assistant director, Global Oncology, Yale Comprehensive Cancer Center, discusses sequencing therapies for patients with HER2-positive breast cancer.

Treatment options for patients with HER2-positive breast cancer has significantly expanded in recent years, Chagpar explains. Though she was told that HER2-positive disease would reach high curative rates, similar to childhood leukemia, Chagpar says she was not convinced. However, she became more optimistic after seeing that combinations of targeted therapies demonstrated significant pathological complete response rates in a number of clinical trials.

Over the next decade, Chagpar predicts that HER2-positive disease will become a chronic disease that can be managed with a selection of targeted therapies.
 



View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Cancer Summaries and Commentaries™: Update from Chicago: Advances in the Treatment of Breast CancerJul 31, 20181.0
Community Practice Connections™: Medical Crossfire®: Translating Lessons Learned with PARP Inhibition to the Treatment of Breast Cancer—Expert Exchanges on Novel Strategies to Personalize CareAug 29, 20181.5
Publication Bottom Border
Border Publication
x